Mucopolysaccharidosis II
Conditions
Brief summary
A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II.
Interventions
DRUGJR-141
IV infusion, 2.0 mg/kg/week
Sponsors
JCR Pharmaceuticals Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
1. Capable of providing written consent by himself (not mandatory for those aged under 20 years at the time of informed consent process, or those who is impossible to obtain consent from the patient himself due to intellectual disabilities associated with MPS II.) 2. In the case of a patient who is under the age of 20 years or from whom it is not possible to obtain consent due to intellectual disabilities associated with MPS II, he may be included if written consent can be provided by legal representative (however, written consent should be obtained from the patient himself too, whenever possible) 3. Males with confirmed diagnosis of MPS II, based on deficient activity of iduronate-2-sulfatase (IDS) in leucocytes, plasma or fibroblasts and/or pathogenic mutations identified in the IDS gene, etc. 4. Naïve patients or patients who are receiving stable enzyme replacement therapy with Elaprase for more than 8 weeks before the observational period starts.
Exclusion criteria
1. Previous engrafted HSCT, excluding those who need enzyme replacement therapy even after HSCT. 2. Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely experience difficulty breathing during the lumbar puncture process. 3. Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity. 4. Patients who have received other investigational product within 4 months before enrollment in the study. 5. Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid | Baseline to 52 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Serum Dermatan Sulfate Levels. | Baseline, 24-26 weeks, 50-52 weeks | — |
| Change From Baseline in Urinary Heparan Sulfate Levels. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Urinary Dermatan Sulfate Levels. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Liver Volumes. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Spleen Volumes. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Cardiac Function. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Serum Heparan Sulfate Levels. | Baseline, 24-26 weeks, 50-52 weeks | — |
| Change From Baseline in Joint Range of Motion. | Baseline, 25 weeks, 52 weeks | — |
| Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid. | Baseline to 25 weeks | — |
| Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid. | Baseline, 25 weeks, 52 weeks | — |
| Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001) | 25, 52 weeks | — |
| Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. ) | 25, 52 weeks | — |
| Drug concentration in Cerebrospinal Fluid. | 25, 52*weeks | \*Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study . |
| Change From Baseline in 6-minute Walk Test Distance. | Baseline, 25 weeks, 52 weeks | Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test |
Countries
Japan
Outcome results
None listed